Brind.

Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.

1 report, 1 independent Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

  • Merck KGaA

    German multinational science and technology company

    Nothing else this week.

  • Immutep

    Biotechnology company

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • GlobeNewswireImmutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP)